Dr. Ivana Magovcevic-Liebisch is Senior Vice President and Head of Global Business Development at Teva Pharmaceuticals. In this capacity, Ivana is responsible for the execution of transactions identified by Teva’s R&D, Global Franchises and US Specialty teams, including the licensing of commercial products, drug candidates and technologies. Prior to Teva, Dr. Magovcevic-Liebisch held several senior positions at Dyax Corp., most recently as Executive Vice President and Chief Operating Officer. Prior to Dyax, Dr. Magovcevic-Liebisch was Director of Intellectual Property and Patent Counsel for Transkaryotic Therapies, Inc., Cambridge, MA.